- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06097364
Badanie mające na celu sprawdzenie, jak dobrze działa odronextamab w połączeniu z chemioterapią i jak jest bezpieczny w porównaniu z rytuksymabem i chemioterapią u dorosłych pacjentów z wcześniej nieleczonym chłoniakiem grudkowym (OLYMPIA-2)
Randomizowane badanie fazy 3, otwarte, mające na celu porównanie skuteczności i bezpieczeństwa odronextamabu (REGN1979), dwuswoistego przeciwciała anty-CD20x anty-CD3, w skojarzeniu z chemioterapią w porównaniu z rytuksymabem w skojarzeniu z chemioterapią u wcześniej nieleczonych pacjentów z chłoniakiem grudkowym (OLYMPIA- 2)
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study.
This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled).
The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study.
The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- The impact from the study drug on quality-of-life and ability to complete routine daily activities
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
Waratah, New South Wales, Australia, 2298
- Calvary Mater Newcastle
-
-
Queensland
-
Benowa, Queensland, Australia, 4217
- Pindara Private Hospital
-
-
-
-
-
Vienna, Austria, 1090
- Universitatsklinik fur Kinder und Jungendheilkunde
-
Wels, Austria, 4600
- Klinikum Wels-Grieskirchen
-
-
Lower Austria
-
Sankt Pölten, Lower Austria, Austria, 3100
- Karl Landsteiner University Hospital St. Poelten
-
-
Styria
-
Graz, Styria, Austria, 8036
- Medical University of Graz
-
Leoben, Styria, Austria, 8700
- Landeskrankenhaus Hochsteiermark
-
-
Tyrol
-
Innsbruck, Tyrol, Austria, 6020
- Innsbruck Medical University
-
-
Upper Austria
-
Linz, Upper Austria, Austria, 4020
- Kepler University Hospital
-
-
-
-
-
Brussels, Belgia, 1000
- Institut Jules Bordet
-
Liège, Belgia, 4000
- Centre Hospitalier Regional de la Citadelle
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgia, 9000
- Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
-
Sint-Niklaas, Oost-Vlaanderen, Belgia, 9100
- Verenigde Ziekenhuizen van Waas en Durme
-
-
West-Vlaanderen
-
Bruges, West-Vlaanderen, Belgia, 8000
- Algemeen Ziekenhuis St Jan Brugge Oostende Av
-
Kortrijk, West-Vlaanderen, Belgia, 8500
- AZ Groeninge
-
-
-
-
-
Rio de Janeiro, Brazylia, 20231050
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva
-
São Paulo, Brazylia, 01323-903
- Hospital Alemao Oswaldo Cruz
-
São Paulo, Brazylia, 08270-070
- Casa de Saude Santa Marcelina
-
São Paulo, Brazylia, 01509-010
- AC Camargo Cancer Center
-
São Paulo, Brazylia, 05403-000
- Clinical Hospital of Medicine School at Sao Paulo University
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazylia, 41253-900
- Hospital Sao Rafael
-
Salvador, Estado de Bahia, Brazylia, 41950-640
- Ensino e Terapia de Inovacao Clinica Amo (Etica)
-
Salvador, Estado de Bahia, Brazylia, 40050-410
- Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
-
-
Federal District
-
Brasília, Federal District, Brazylia, 70200-730
- Hospital Sirio Libanes Brasilia
-
Brasília, Federal District, Brazylia, 70390-140
- Instituto DOr de Pesquisa e Ensino Df Star
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazylia, 30380-472
- Instituto Mario Pena de Ensino Pesquisa e Inovacao
-
Uberlândia, Minas Gerais, Brazylia, 38408-008
- Centro Oncologico do Triangulo (COT) - Uberlandia
-
-
Paraná
-
Curitiba, Paraná, Brazylia, 81520-060
- Hospital Erasto Gaertner
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brazylia, 59062-000
- Liga Norte Riograndense Contra o Cancer
-
-
Rio Grande do Sul
-
Bento Gonçalves, Rio Grande do Sul, Brazylia, 95700-084
- Instituto Tacchini de Pesquisa em Saude
-
Passo Fundo, Rio Grande do Sul, Brazylia, 99010-080
- Instituto do Cancer em Hospital Sao Vicente de Paulo
-
Porto Alegre, Rio Grande do Sul, Brazylia, 90035-903
- Hospital de Clinicas de Porto Alegre
-
-
Santa Catarina
-
Joinville, Santa Catarina, Brazylia, 89201-260
- Centro de Hematologia e Oncologia
-
Lages, Santa Catarina, Brazylia, 88501-001
- Animi Unidade de Tratamento Oncologico Ltda
-
-
São Paulo
-
Barretos, São Paulo, Brazylia, 14784-400
- Fundacao Pio XII Hospital de Amor
-
Jaú, São Paulo, Brazylia, 17210-080
- Amaral Carvalho Hospital
-
Ribeirão Preto, São Paulo, Brazylia, 14048-900
- Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
-
-
-
-
Las Condes
-
Santiago, Las Condes, Chile, 7620157
- Hospital Clinico Universidad de Los Andes
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 7560907
- Centro Oncologia de Precision Universidad Mayor
-
Santiago, Santiago Metropolitan, Chile, 7580206
- Inmunocel
-
Santiago, Santiago Metropolitan, Chile, 7550000
- Pontificia Universidad Catolica de Chile
-
-
-
-
North Central Czech Republic
-
Hradec Králové, North Central Czech Republic, Czechy, 50005
- University Hospital Hradec Kralove
-
-
South Moravian
-
Brno, South Moravian, Czechy, 62500
- University Hospital Brno
-
-
-
-
-
Grenoble, Francja, 38043
- Centre Hospitalier Universitaire de Grenoble
-
Le Puy-en-Velay, Francja, 43012
- Centre Hospitalier Emile Roux
-
Lens, Francja, 62300
- Centre Hospitalier de Lens (Centre Hospitalier Dr Schaffner dLens)
-
Paris, Francja, 75010
- Hopital Saint Louis
-
Pessac, Francja, 33600
- Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Sud - Hôpital Haut Lévêque
-
Saint-Etienne, Francja, 42055
- CHU de Saint-Etienne
-
Saint-Nazaire, Francja, 44600
- Centre Hospitalier de Saint Nazaire
-
-
Alpes Maritimes
-
Cannes, Alpes Maritimes, Francja, 06400
- Cannes Hospital (Centre Hospitalier Cannes Simone Veil)
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, Francja, 37044
- CHRU de Tours
-
-
Gard
-
Nîmes, Gard, Francja, 30029
- Institut de Cancerologie du Gard
-
-
New Aquitaine
-
Mont-de-Marsan, New Aquitaine, Francja, 40024
- Centre Hospitalier de Mont-de-Marsan
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Francja, 44093
- Nantes University Hospital
-
-
Pontoise
-
Cergy-Pontoise, Pontoise, Francja, 95300
- The Novo Hospital North West Val Deoise
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, Francja, 95100
- Hopital Victor Dupouy Argenteuil
-
-
-
-
-
Lugo, Hiszpania, 27003
- Hospital Universitario Lucus Augusti
-
Madrid, Hiszpania, 28027
- Clinica Universidad de Navarra - Madrid
-
Madrid, Hiszpania, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Hiszpania, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Hiszpania, 28031
- Hospital Universitario Infanta Leonor
-
Madrid, Hiszpania, 28040
- Hospital Universitario Fundacion Jimenez Diaz
-
Ourense, Hiszpania, 32005
- Complexo Hospitalario Universitario de Ourense
-
Pamplona, Hiszpania, 31008
- Clinica Universidad de Navarra- Pamplona
-
Salamanca, Hiszpania, 37007
- Hospital Universitario de Salamanca
-
Seville, Hiszpania, 41009
- Hospital Universitario Virgen Macarena
-
Valencia, Hiszpania, 46009
- Instituto Valenciano de Oncologia
-
Valencia, Hiszpania, 46010
- Hospital Clinico Universitario de Valencia
-
-
Andalusia
-
Seville, Andalusia, Hiszpania, 41013
- Hospital Universitario Virgen del Rocio
-
-
Barcelona
-
Sabadell, Barcelona, Hiszpania, 08208
- Parc Tauli Sabadell Hospital Universitari
-
Terrassa, Barcelona, Hiszpania, 08221
- Hospital Universitari Mutua Terrassa
-
-
Bizkaia
-
Barakaldo, Bizkaia, Hiszpania, 48903
- Cruces University Hospital (Hospital Universitario Cruces)
-
-
Madrid
-
Majadahonda, Madrid, Hiszpania, 28222
- Hospital Universitario Puerta de Hierro - Majadahonda
-
Pozuelo de Alarcón, Madrid, Hiszpania, 28223
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona, Navarre, Hiszpania, 31008
- Hospital Universitario de Navarra
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Hiszpania, 33011
- Hospital Universitario Central de Asturias
-
-
Valencia
-
Alicante, Valencia, Hiszpania, 03010
- Hospital General Universitario Doctor Balmis Alicante
-
-
-
-
-
Beersheba, Izrael, 84101
- Soroka University Medical Center
-
Haifa, Izrael, 3109601
- Rambam Health Care Campus
-
Jerusalem, Izrael, 91200
- Hadassah Medical Center
-
Petah Tikva, Izrael, 49100
- Rabin Medical Center
-
Tel Aviv, Izrael, 64239
- The Tel Aviv Sourasky Medical Center
-
Tel Aviv, Izrael, 6971028
- Assuta Medical Centers
-
-
Jerusalem
-
Jerusalem, Jerusalem, Izrael, 9103102
- Shaare Zedek Medical Center
-
-
-
-
-
Kiel, Niemcy, 24116
- Stadtisches Krankenhaus Kiel
-
Neuss, Niemcy, 41462
- MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH
-
-
-
-
-
Bydgoszcz, Polska, 85-168
- Szpital Uniwersytecki Nr2 Bydgoszcz
-
Gdansk, Polska, 80-952
- Uniwersyteckie Centrum Kliniczne, Building of the Non-Invasive Medicine Center
-
Katowice, Polska, 40-519
- Pratia Onkologia Katowice
-
Lodz, Polska, 93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
-
Lublin, Polska, 20-954
- Centrum Innowacyjnych Terapii Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
-
Warsaw, Polska, 02781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa
-
Wałbrzych, Polska, 58-300
- Szpital Szpecjalistyczny w Walbrzychu
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polska, 30-510
- Matopolskie Centrum Medyczne S.C.
-
-
Wielkopolska
-
Skorzewo, Wielkopolska, Polska, 60185
- Aidport Sp. z o.o.
-
-
-
-
Florida
-
Plantation, Florida, Stany Zjednoczone, 33322
- Boca Raton Clinical Research (BRCR) Global
-
-
Indiana
-
Noblesville, Indiana, Stany Zjednoczone, 46062
- Investigative Clinical Research of Indiana
-
-
Kansas
-
Wichita, Kansas, Stany Zjednoczone, 67214
- Cancer Center of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40536
- University of Kentucky
-
-
Michigan
-
Detroit, Michigan, Stany Zjednoczone, 48202
- Henry Ford Health System
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Cancer and Hematology Centers of Western Michigan
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- Center for Oncology and Blood Disorders
-
-
Utah
-
Ogden, Utah, Stany Zjednoczone, 84405
- Community Cancer Trials of Utah
-
-
Wisconsin
-
Waukesha, Wisconsin, Stany Zjednoczone, 53188
- Prohealth Care Inc
-
-
-
-
-
Khon Kaen, Tajlandia, 40002
- Khon Kaen University
-
-
Krung Thep Maha Nakhon [Bangko]
-
Bangkok, Krung Thep Maha Nakhon [Bangko], Tajlandia, 10330
- Chulalongkorn University
-
-
-
-
-
Kaohsiung City, Tajwan, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City, Tajwan, 80756
- Kaohsiung Medical University Hospital
-
New Taipei City, Tajwan, 23561
- Taipei Medical University - Shuang Ho Hospital
-
Taipei, Tajwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Tajwan, 11490
- Tri-Service General Hospital
-
Taipei, Tajwan, 11696
- Taipei Medical University Multipal Wan Fang University
-
-
-
-
-
Ankara, Turcja (Türkiye), 06100
- Liv Hospital Ankara
-
Istanbul, Turcja (Türkiye), 34365
- VKV American Hopital
-
Istanbul, Turcja (Türkiye), 34418
- Istanbul University
-
Kayseri, Turcja (Türkiye), 38039
- Erci̇yes Uni̇versi̇ty
-
Samsun, Turcja (Türkiye), 55270
- Ondokuz Mayıs University
-
Zonguldak, Turcja (Türkiye), 67100
- Zonguldak Bulent Ecevit University
-
-
Ankara
-
Mamak, Ankara, Turcja (Türkiye), 06620
- Ankara University Faculty of Medicine
-
Yenimahalle, Ankara, Turcja (Türkiye), 06200
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
-
Central Anatolia
-
Ankara, Central Anatolia, Turcja (Türkiye), 06100
- Gazi University
-
-
Mersin
-
Mezitli, Mersin, Turcja (Türkiye), 33200
- VM Medical Park Mersin Hospital
-
-
Serdivan
-
Sakarya, Serdivan, Turcja (Türkiye), 54050
- Sakarya University
-
-
Suleymanpasa
-
Tekirdağ, Suleymanpasa, Turcja (Türkiye), 59100
- Tekirdag Namik Kemal University Hospital
-
-
-
-
-
Milan, Włochy, 20141
- Istituto Europeo di Oncologia
-
Milan, Włochy, 20162
- ASST Grande Ospedale Metropolitano Niguarda - Main Address
-
Milan, Włochy, 20122
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Modena, Włochy, 41124
- A.O.U. di Modena
-
Naples, Włochy, 80131
- Federico II University
-
Perugia, Włochy, 06132
- Azienda Ospedaliera di Perugia
-
Pisa, Włochy, 56126
- University of Pisa, Section of Hematology
-
Potenza, Włochy, 85100
- Azienda Ospedaliera Regionale San Carlo
-
Ravenna, Włochy, 48121
- UO Ematologia Ravenna
-
Reggio Emilia, Włochy, 42123
- Azienda Unita Sanitaria Locale Irccs Arcispedale Santa Maria Nuova
-
Rome, Włochy, 00161
- Azienda Osperdaliero-Universitaria Policlinico Umberto 1
-
Udine, Włochy, 33100
- Azienda Sanitaria Universitaria del Friuli Centrale
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Włochy, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
-
Piedmont
-
Turin, Piedmont, Włochy, 10137
- Azienda Ospedaliera Ordine Mauriziano Torino, Presidio Umberto I of Turin
-
-
Sicily
-
Palermo, Sicily, Włochy, 90127
- Azienda Ospedaliera Universitario Policlinico Palermo
-
-
-
-
-
Aberdeen, Zjednoczone Królestwo, AB25 2ZN
- NHS Grampian: Aberdeen Royal Infirmary
-
-
Cornwall
-
Truro, Cornwall, Zjednoczone Królestwo, TR1 3LJ
- Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
-
-
London
-
Uxbridge, London, Zjednoczone Królestwo, UB8 3NN
- The Hillingdon Hospitals NHS Foundation Trust
-
-
West Midlands
-
Birmingham, West Midlands, Zjednoczone Królestwo, B15 2SY
- University Hospitals Birmingham NHS Foundation Trust
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Key Inclusion Criteria:
-
Have diagnosis of cluster of differentiation 20 positive (CD20+) FL grade 1-3a, stage II bulky or stage III / IV
- For Part 1A: previously untreated participants who have Follicular Lymphoma International Prognostic Index (FLIPI)-1 score of 3 to 5, or R/R FL
- For Part 1B: previously untreated participants who have FLIPI-1 score of 3 to 5
- For Part 2: previously untreated participants who have FLIPI-1 score of 0 to 5
-
Have measurable disease on cross sectional imaging documented by diagnostic computed tomography [CT], or magnetic resonance imaging [MRI] imaging, as described in the protocol
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
-
Adequate bone marrow and hepatic function.
Key Exclusion Criteria:
- Participants with central nervous system lymphoma or leptomeningeal lymphoma
- Participants with histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
- Participants with Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), grade 3b follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma
- Recent major surgery and history or organ transplantation
- A malignancy other than NHL unless the participant is adequately and definitively treated and any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Odronextamab + Chemotherapy
Part 1 of the study includes ordonextamab dose escalation for participants with previously untreated FL and relapsed/refractory FL (Part 1A only) followed by a randomized exploration of 2 regimens of odronextamab (Odro) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with the objective of dose optimization (Part 1B) in previously untreated patients with FL. |
Administered by intravenous (IV) infusion
Inne nazwy:
Administered by IV infusion
Inne nazwy:
Administered by IV infusion
Inne nazwy:
Administered orally (PO)
Inne nazwy:
|
|
Aktywny komparator: Rituximab + Chemotherapy
In Part 2 only, participants will be randomized 1:1:1 to receive rituximab (R) with chemotherapy (CHOP), followed by rituximab monotherapy maintenance. |
Administered by intravenous (IV) infusion
Inne nazwy:
Administered by IV infusion
Inne nazwy:
Administered by IV infusion
Inne nazwy:
Administered orally (PO)
Inne nazwy:
Administered by IV infusion, or subcutaneous (SC)
Inne nazwy:
Administered by IV infusion
Inne nazwy:
|
|
Eksperymentalny: Odronextamab + Chemotherapy + Maintenance
In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy [CHOP, or cyclophosphamide, vincristine, and prednisone (CVP)], followed by odronextamab monotherapy maintenance. |
Administered by intravenous (IV) infusion
Inne nazwy:
Administered by IV infusion
Inne nazwy:
|
|
Eksperymentalny: Odronextamab + Chemotherapy + No maintenance
In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy (CHOP, or CVP) without maintenance. |
Administered by intravenous (IV) infusion
Inne nazwy:
Administered by IV infusion
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy
Ramy czasowe: Up to 35 days
|
Part 1, DLT period |
Up to 35 days
|
|
Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapy
Ramy czasowe: Up to 2 years
|
Part 1, Treatment period |
Up to 2 years
|
|
Severity of TEAEs of odronextamab in combination with chemotherapy
Ramy czasowe: Up to 2 years
|
Part 1, Treatment period |
Up to 2 years
|
|
Complete Response rate at 30 months (CR30) assessed by independent central review (ICR)
Ramy czasowe: Up to 30 months
|
Part 2 |
Up to 30 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall Survival (OS)
Ramy czasowe: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
CR30 as assessed by local investigator
Ramy czasowe: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Incidence of TEAEs
Ramy czasowe: Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Severity of TEAEs
Ramy czasowe: Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Change in Patient Global Impression of Severity (PGIS)
Ramy czasowe: Up to 5 years
|
Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe). |
Up to 5 years
|
|
Change in Patient Global Impression of Change (PGIC)
Ramy czasowe: Up to 5 years
|
Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse. |
Up to 5 years
|
|
BOR as assessed by ICR
Ramy czasowe: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Odronextamab concentrations in serum when administered with chemotherapy
Ramy czasowe: Up to 30 months
|
Part 1, Maintenance period and Part 2, Induction period |
Up to 30 months
|
|
Odronextamab concentrations in serum when administered as monotherapy
Ramy czasowe: Up to 30 months
|
Part 1 and Part 2, Maintenance period |
Up to 30 months
|
|
Incidence of anti-odronextamab antibodies (ADAs)
Ramy czasowe: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Titers of ADAs to odronextamab
Ramy czasowe: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Incidence of neutralizing antibodies (NAb) to odronextamab
Ramy czasowe: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Best overall response (BOR) as assessed by the investigator
Ramy czasowe: Up to 30 months
|
Part 1, end of Induction period and end of Maintenance period |
Up to 30 months
|
|
Progression free survival (PFS) as assessed by ICR
Ramy czasowe: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Change in patient reported physical functioning scale scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC-QLQ-C30)
Ramy czasowe: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
PFS as assessed by local investigator
Ramy czasowe: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Event-free survival (EFS) as assessed by ICR
Ramy czasowe: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
EFS as assessed by local investigator
Ramy czasowe: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
BOR as assessed by local investigator
Ramy czasowe: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Duration of response (DOR) assessed by ICR
Ramy czasowe: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
DOR as assessed by local investigator
Ramy czasowe: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Time to next anti-lymphoma treatment (TTNT)
Ramy czasowe: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Change in patient reported health related quality of life (HRQoL) as measured by EORTC-QLQ-C30
Ramy czasowe: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in cancer disease as measured by EORTC-QLQ-C30
Ramy czasowe: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in treatment related symptoms as measured by EORTC-QLQ-C30
Ramy czasowe: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in patient-reported lymphoma disease as measured by the Lymphoma Subscale of the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS)
Ramy czasowe: Up to 5 years
|
Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Change in treatment-related symptoms as measured by the FACT-LymS
Ramy czasowe: Up to 5 years
|
Part 2 The FACT-LymS includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Change in patient-reported general health status per EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
Ramy czasowe: Up to 5 years
|
Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Up to 5 years
|
|
Change in patient-reported treatment side effects burden per Functional Assessment of Cancer Therapy-General Global Population Item 5 (FACT-G GP5)
Ramy czasowe: Up to 5 years
|
Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
|
Change in score of the FACT-G GP5 item in the patient population
Ramy czasowe: Up to 5 years
|
Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Clinical Trial Management, Regeneron Pharmaceuticals
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Procesy patologiczne
- Nowotwory
- Atrybuty choroby
- Choroby układu odpornościowego
- Nowotwory według typu histologicznego
- Choroby limfatyczne
- Zaburzenia limfoproliferacyjne
- Zaburzenia immunoproliferacyjne
- Chłoniak nieziarniczy
- Chłoniak
- Stany patologiczne, oznaki i objawy
- Choroby hemowe i limfatyczne
- Nawrót
- Chłoniak, Pęcherzykowy
- Aminokwasy, peptydy i białka
- Białka
- Organiczne chemikalia
- Związki heterocykliczne
- Związki heterocykliczne, 2-ring
- Związki heterocykliczne, sterowanie stopieniem
- Węglowodory
- Węglowodory, cykliczne
- Węglowodany
- Alkaloidy
- Policykliczne aromatyczne węglowodory
- Węglowodory, aromatyczne
- Związki policykliczne
- Glikozydy
- Indole
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Ciąży
- Ciężarne
- Steroidy
- Związki sterownika
- Mostki fosforamidu
- Związki musztardy azotu
- Związki musztardy
- Węglowodory, uboczne
- Fosforamidy
- Związki okorosfosforowe
- Ciąży
- Ciąży
- Vinca alkaloidy
- Sesologanina alkaloidy tryptaminy
- Alkaloidy indole
- Indolizicyny
- Indolizyny
- Antracykliny
- Naftaceny
- Aminoglikozydy
- Przeciwciała, monoklonalne, mysie
- Daunorubicyna
- Prednizolon
- Rytuksymab
- Prednizon
- Cyklofosfamid
- Doksorubicyna
- Winkrystyna
- Metyloprednizolon
Inne numery identyfikacyjne badania
- R1979-ONC-2075
- 2022-502113-28-00 (Inny identyfikator: EUCT Number)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Ramy czasowe udostępniania IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Kryteria dostępu do udostępniania IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
- ANALITYCZNY_KOD
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .